Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

After the fall of President Bashar al-Assad, old alliances have crumbled, and global powers are figuring out their relationships with Syria’s new de facto leaders. The Old General watched over ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.